---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-027203"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2026-01-28T23:59:59+00:00"
generated_at: "2026-05-16T06:59:22.280887+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tempest shareholders approve share issuance for asset purchase and extend rights plan

## Summary
- Approved issuance of 8,268,495 common shares for Asset Purchase Agreement with Erigen LLC and Factor Bioscience Inc.
- Stockholders extended limited duration rights plan to October 10, 2026.
- Amendment to 2023 Equity Incentive Plan approved, increasing share reserve by 1,410,000 shares.
- Geoff Nichol elected Class I director with 1,003,845 votes for; broker non-votes 1,075,928.
- Advisory say-on-pay approved with 816,856 votes for, 428,524 against.

## SEC filing metadata
- accession: 0001193125-26-027203
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2026-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- confidence: high
- sec_items: 3.03, 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312526027203/0001193125-26-027203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312526027203/d70064d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-027203
- JSON: https://secwatch.observer/filing/0001193125-26-027203.json
- Plain text: https://secwatch.observer/filing/0001193125-26-027203.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.